American Journal of Biology and Natural Sciences
https://biojournals.us/index.php/AJBNS
ISSN: 2997-7185

The Role of Molecular Biology and Biotechnology in Enhancing Pathology Analysis for Cancer Research and Treatment

Baneen Abbas's Hussain Kazem[1], Salsbel Slahaldin M. Amin[2], Aesha Dler Muhamad Salah[3], Athraa Badeaa Hunoosh[4]
[1]University of kufa College of science Department pathology analysis, Iraq
[2]University of Sulaimani college of Science Department of Biology, Iraq
[3]University of Duhok college of Science Department of Biology, Iraq
[4]University of Fallujah College of Applied Sciences Department of Biotechnology, Iraq

Received: 2025, 15, Jul
Accepted: 2025, 21, Aug
Published: 2025, 29, Sep

Annotation: Molecular biology—the study of living organisms at the cellular level—and biotechnology—the application of biological systems to technological innovation—remain pivotal in unraveling the ever-expanding genetic framework of cancer. These disciplines parallel the growth of data science, empowering scientific progress and enabling a multidisciplinary understanding of malignancy in the postgenomic era. The application of molecular biology and biotechnology has already elucidated fundamental aspects of cancer biology and has begun to revolutionize prevention, detection, and treatment strategies.

The pathology department plays a critical role in the preanalytical phase of molecular analyses, an essential step toward delivering personalized treatment and developing innovative therapies. The success of contemporary molecular and proteomic techniques largely depends on the quality of biological material, which may

be derived from fresh or formalin-fixed, paraffin-embedded (FFPE) tissues. Consequently, tissue fixation and preservation undergo a rigorously standardized preparation process. Enhancements in preanalytical standardization and quality control have markedly reduced the rate of error associated with molecular tests. Molecular biology continues to provide an extensive repository of information pertinent to cancer, much of which continues to transform clinical oncology and treatment protocols.

1. Introduction to Molecular Biology and Biotechnology

Molecular biology investigates the molecular basis of biological activity in and between cells, including molecular synthesis, modification, mechanisms, and interactions. Molecular biology techniques are used within a wider range of related scientific fields and medical applications. Biotechnology utilizes cellular and biomolecular processes to develop technologies and products that help improve the health of living organisms and the planet.

Molecular biology and related techniques provide a means to understand many important biological processes, including those involved in cancer. Much progress has been made recently in detecting molecular events related to tumor development and in the discovery of drugs targeting molecular pathways important in the pathogenesis of several types of cancers. As a result, there is an increasing requirement for standardization and quality control of molecular biology techniques. Tumor progression is considered a multistep process characterized by the accumulation of genetic abnormalities that enable tumor cells to evolve to a more malignant phenotype. Genomics and proteomics provide powerful tools to understand the molecular basis for tumor progression but both techniques require high-quality tissues that are handled and preserved in an adequate manner. Pathology departments are required to manage tissue preservation and initial tissue analysis in order to allow high-quality molecular analyses and to provide good evaluation of pathology parameters. Major advances in the techniques, reagents, and equipment for molecular analyses have played a substantial role in the reduction of analytical errors by approximately tenfold and have been facilitated the exponential growth in the use of molecular pathology. Molecular biology plays a crucial role in cancer therapy, as it can reveal the many genetic interactions that result in oncogene activation. Oncogene activation has many causes, such as viral infection involvement and proto-oncogene mutation. It also helps classify oncogenes and tumor suppressor genes, which permit the understanding of their functions in different types of cancers. Molecular biology can also characterize molecular and genetic changes such as chromosomal translocations and mutations that provide essential information needed for targeted therapy and medication development. Techniques including RNA analysis, immunohistochemistry, and next-generation sequencing aid in prognosis and diagnosis; RNA profiling in breast cancer effectively predicts the likelihood of recurrence, providing a more reliable prediction than conventional techniques, and next-generation sequencing identifies gene mutation status and other important diagnostic

information in lung cancer. Molecular biology enables new treatment strategies that have shifted the general approach to cancer therapy beyond traditional chemotherapy to include tools such as CRISPR-Cas9 gene editing, targeted pharmaceutical agents, immunotherapy, and apoptosis-inducing treatments. Advancements in molecular biology continue to transform cancer therapy and contribute to the reduction of cancer's complexity [1] [2].

2. Understanding Cancer Pathology

At the cellular level, normal tissue homeostasis relies on a predisposed function of several genes regulating cell growth, proliferation, differentiation, and apoptosis. Genetic and epigenetic alterations affecting crucial genes enable the transformation of a normal cell into a highly malignant derivative that exhibits key properties such as limitless replicative potential, self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of apoptosis, and the capability to invade and metastasize to distant sites. Alterations in proto-oncogenes, tumor-suppressor genes, and stability genes contribute to the pathogenesis of virtually all human tumors. Pathological examination of tumors remains the gold standard for accurate diagnosis, classification and grading. Thus, in the diverse armamentarium of cancer research, molecular biology techniques and biotechnology find extensive applications—from the elucidation of biological and biochemical mechanisms underlying the disease to the development of diagnostic screening and experimental assays [3].

3. Advancements in Molecular Techniques

Cancer results from genomic instability acquired during tumor initiation and progression. Although most solid tumors originate from epithelial tissues, hematopoietic and mesenchymal neoplasms also exist. Furthermore, a single neoplasm comprises diverse phenotypic and genotypic subpopulations. Consequently, the tumor microenvironment engages significantly in the oncogenic process, with cancer cells adapting their metabolism to survive, proliferate, and develop resistance [3].

An emerging understanding of the molecular mechanisms underlying neoplastic development, dissemination, and therapeutic response has significantly influenced the clinical management of solid tumors. Transcriptional and protein expression profiles offer insights into the biological basis of cancer, enabling novel diagnostic and prognostic definitions. Genetic alterations have become fundamental in refining tumor classification, guiding targeted drug development, and identifying tumoral properties predictive of therapeutic efficacy. Tumor-agnostic approaches, which identify molecular alterations regardless of location and histology, exemplify this shift towards precision oncology [1].

A diversity of techniques—ranging from next-generation sequencing and DNA microarrays to mass spectrometry and protein arrays—has been utilized to detect molecular alterations, expression patterns, metabolites, and interactions. Transcriptomics and proteomics have not only enhanced the understanding of cellular processes affected during tumorigenesis and progression but also driven clinical research towards systems biological approaches capable of integrating genetic and epigenetic changes into complex biological models. Identifying genomic, transcriptomic, and proteomic alterations has informed the selection of driver genes and processes pivotal in tumorigenic mechanisms. Similarly, monitoring metabolite variations reveals affected metabolic pathways in carcinogenesis.

3.1. Genomic Sequencing

Genomic sequencing encompasses a suite of quantitative methods for analyzing cancer-specific alterations in DNA and RNA through direct sequencing of tissue or circulating tumor DNA (ctDNA). As a central tool in modern cancer pathology, it enables characterization of cellular mutation profiles, quantification of gene expression, and complete analysis of the patient-specific transcriptome. Understanding DNA and RNA provides insights into the hallmarks of tumor biology, including resistance to growth suppression, replicative immortality, immune evasion, and

deteriorating genome stability.

Since the mid-2000s, next-generation sequencing (NGS) has had a transformative impact on biomedical research. Technologies evolving from microarray platforms enable broad profiling of the genome, including variants, structural aberrations, methylation changes, and the transcriptome. Consequently, NGS became integral to pathological evaluation of patient habitats, frequently serving as a first-line characterizer [4]. Because mutations are dispersed throughout the genome, unbiased genome-wide methods provide comprehensive information, whereas single-mutation assays demand indefinite expansion and parallelization to maintain coverage. In clinical laboratories, cheap and available NGS reagents have supplanted hotspot panels for tumor characterization and drug target identification. Standard variant-calling pipelines enable broad genomic characterization with high specificity and sensitivity. Larger sequencing instruments—despite longer turnaround times—grant access to whole-genome characterization, furnishing unbiased molecular portraits and facilitating objective agent discovery across all genomic regions. Comprehensive clinical annotation supports discovery of new compounds and biomarkers. For mutant transcripts, RNA sequencing delineates aberrations at the expression and fusion levels, also supplying insight into tumor-infiltrating immune components [5].

Despite broad support from cancer agencies, challenges remain. High tissue requirements render tested samples practically exhausted after a single analysis. Unfavorable tissue preservation and neoadjuvant therapies diminish test performance, further taxonomizing each variant call with additional methods or examinations.

3.2. Proteomics

Cancer is a life-threatening disease affecting millions globally and is often characterized by uncontrolled cell division coupled with reduced apoptosis. Special groups of cancers include hereditary cancers, early childhood cancers, and cancers from different tissue sites with unknown etiology and development mechanisms. Diagnostic procedures generally include histopathology analysis, where cancer cells are studied microscopically through the examination of tissue structures and cells. Early diagnosis of cancer significantly determines the likelihood of patient cure and reduces mortality rates. Advances in molecular biology and biotechnology have provided innovative techniques such as proteomics and genomic sequencing. These tools enable the highly sensitive and specific analysis and diagnosis of cancer at molecular levels, facilitating early detection and appropriate treatment selection.

Proteomics is a novel detection tool aimed at the qualitative and quantitative identification of proteins in biological specimens. It offers valuable assistance in cancer research by identifying cancer-specific biomarkers—for instance, proteins secreted specifically by cancerous breast cells previously studied by lung cancer researchers. Proteomics has the potential to detect cancer in serum at an early stage and to predict its development. The delivery of targeted drugs directly to cells that might stimulate tumor growth and the detection of patients' cancer at an early stage can be accomplished using proteomic techniques. [6][7][8]

3.3. Metabolomics

Analysis of the chemical fingerprints that cellular processes leave behind, specifically the study of their small-molecule metabolite profiles. Metabolomics enables the exploration of hundreds of compounds and their concentrations in a biological sample, providing information on the continuous molecular changes during disease progression.

High-throughput technologies utilize the unique characteristics and composition of each class of metabolites (amino acids, fatty acids, and sugars) to examine them. Liquid or gas chromatography combined with mass spectrometric detection is most commonly applied in metabolomics studies. The potential of metabolomics is enormous because it reflects not only the genetic background of the tumor but also environmental factors and tumor-related endogenous regulation. Recent innovations in detection and quantification methods have led to a growing number of

metabolomics investigations on various cancers including colorectal, lung, breast, bladder, gastric, esophageal, melanoma, and head and neck cancers. [9][10][11]

4. Biotechnology Applications in Cancer Research

Biotechnology provides powerful tools that advance understanding of cancer biology and create novel research and treatment strategies. Gene editing with CRISPR-Cas9 enables precise genome modifications to investigate gene functions in tumor progression, metastasis, and drug resistance [2]. Gene therapy approaches introduce functional genes to inhibit tumor growth or restore tumor suppressor functions. Monoclonal antibodies target overexpressed or mutated proteins and recruit the immune system to eradicate tumors. These technologies complement classical molecular and cellular techniques, accelerating the discovery of cancer biomarkers, epidemiological mechanisms, and novel therapeutic targets.

By integrating experimental innovations into routine practice, biotechnology greatly enhances the characterization and treatment of cancer. Molecular and physiological knowledge from biomedicine forms the basis of advances achievable only with biotechnology. These developments optimize cancer diagnosis and therapy and deepen the understanding of the disease.

4.1. CRISPR and Gene Editing

CRISPR, short for Clustered Regularly Interspaced Short Palindromic Repeats, is a type of DNA sequence found in bacteria that lives alongside the Cas9 DNA-cleaving enzyme [12]. Scientists can program Cas9 nucleases with a single guide RNA molecule that binds to a desired complimentary DNA sequence at almost any location in the genome. Because of this, CRISPR-Cas9 is one of the leading gene editing technologies for cancer research due to its ability to remove or insert genetic material.

In addition to CRISPR-Cas9, researchers are investigating other CRISPR-Cas types that differ in function from Cas9, including Cas13, Cas12b, and Cas14. This work includes developing variations to a native Cas9 that show greater specificity and efficiency such as Cas9-NG, xCas9, and XNG-Cas9, which collectively further enhance CRISPR's versatility [13].

Gene editing offers tools to unravel the mechanisms underpinning cancer and identify novel targets. Models based on genetically engineered mice or human cells with individual driver mutations have revealed pathophysiological phenotypes and some clinical features of cancers. CRISPR-Cas9 facilitates the creation of disease models in nonmammalian species and permits cancer modeling through targeted gene activation [14]. Deployment also supports the discovery of drug-resistance mechanisms and approaches to overcome them via genome-wide loss-of-function screens and the introduction of combinations of cancer mutations and defined resistance alleles into preexisting models.

4.2. Gene Therapy

Gene therapy aims to alleviate cancer by reinstating or amplifying tumor suppressor genes that inhibit the proliferation of malignant cells. This approach often employs viral vectors to transport these genes into cancerous cells, and retroviruses such as MoMLV have been successfully utilized to deliver therapeutic genes in cancer treatment and gene therapy contexts [2].

4.3. Monoclonal Antibodies

Monoclonal antibodies represent a powerful therapeutic approach in oncology. As specific proteins produced by B cells in response to tumor antigens, these identical clones derived from a single ancestor B cell can be used to target cancer cells. The synthesis of monoclonal antibodies through genetic engineering prevents rejection by the patient's immune system, enabling clinicians to focus the body's immune defenses specifically on cancer cells.

The utility of monoclonal antibodies extends beyond their direct involvement in mounting an immune response against cancer. In diagnostics, these antibodies serve as targeting agents for

contrast substances, such as radioactive isotopes or paramagnetic substances, in brain and prostate magnetic resonance imaging, and as transporters of chemotherapeutic agents in cancer therapy for brain, prostate, breast, ovarian, colorectal, and lung tumors. Precise and early molecular analysis of cancer tissues underpins these approaches, with techniques such as viral or retroviral gene therapy and CRISPR protein guides highlighting the critical support of molecular biology and biotechnology for conventional pathology analysis.

5. Molecular Diagnostics in Cancer

Molecular diagnostics has emerged as a promising approach for screening and early cancer detection. Biomarkers of cancer presence constitute a distinctive repertoire of molecules, including DNA mutations and methylation, RNA, protein, and metabolites [2]. Rapidly proliferating cancer cells release molecules or deposit them in accessible body fluids such as blood, urine, or saliva. A blood test, known as a “liquid biopsy”, capable of capturing circulating tumour DNA (ctDNA) of small tumours could facilitate early detection. Pathology still represents the reference discipline for cancer diagnosis. Several techniques are widely utilized: histopathology analysis remains the gold standard to confirm tumour invasion, assessing immune cell infiltration or identifying rare tumour cells through hematoxylin and eosin staining, which is fundamental for tumour classification and supports decisions regarding further specific immunohistochemistry or molecular investigations. Immunohistochemistry continues to play a primary role—examples include estrogen and progesterone hormone receptors or human epidermal growth factor receptor 2 as indicators supporting prognosis, prediction, and treatment decisions in breast cancer. For molecular approaches, the more common procedure involves identifying target mutations by molecular biology or sequencing techniques to guide clinicians in defining the most appropriate adjuvant treatment [1].

5.1. Biomarkers for Early Detection

Confirming the initiation and progression of cancer typically requires the detection of molecular markers, which characterize tumor development and serve as predictive factors regarding patient survival. The ability to diagnose cancer provides a mechanism for predicting disease outcomes and offers an opportunity to understand the transition from normal to abnormal tissue. This information allows clinicians to adjust therapies, leveraging the understanding of the pathophysiological changes that occur in disease. A crucial advance in patient prognosis and treatment involves the identification of cancerous markers for early discovery via molecular and immunohistochemical techniques. Biomarkers offer a practical approach for early detection by recognizing the disease at its incipient stages, often before the manifestation of physical symptoms. Researchers have underscored the importance of finding novel biomarkers for clinical diagnosis, anti-cancer drug discovery and formulation, and studying the etiology of malignancies.

Early detection aims to identify the minimal alterations indicative of significant cancer or precancerous states to reduce mortality and morbidity. Modern imaging technologies can detect only cancerous tissues comprising more than ten cells and may overlook tumors below this threshold. Biomarkers possess the capability to recognize the presence of illness in asymptomatic individuals, to diagnose disease within tissue sections, and to monitor the efficacy of therapeutic interventions. Diagnostic markers thus facilitate the non-invasive identification of early-stage cancers, enabling the timely application of effective treatment protocols. It has been observed that the discovery of such indicators often proceeds through data-driven approaches rather than being guided solely by predefined biological hypotheses [15].

5.2. Liquid Biopsies

Recent advances in the management of cancer patients have focused on early detection and identification of therapeutic targets. Liquid biopsy is a minimally invasive technique that offers an integrated view of tumor lesions in real time, along with a comprehensive molecular profile. Oncogenic alterations can be detected in the blood and/or other body fluids, enabling cancer

diagnosis, prognosis, or treatment monitoring to be assessed from a simple blood test. Liquid biopsies constitute a clinically relevant source of tumor-derived biomarkers, such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), extracellular vesicles (EVs), circulating cell-free microRNAs (cfmiRNAs), and tumor-educated platelets (TEPs). Tumor genotyping can be performed on these analytes with different molecular biology techniques, including next-generation sequencing (NGS) or droplet digital PCR (ddPCR). Overall, liquid biopsies offer an alternative and complementary tool for cancer management. The study of specific biomarkers by high-throughput techniques may guide clinicians in disease evolution monitoring during targeted therapy administration [16]. Over two decades, cancer diagnostics in the era of precision medicine has progressed significantly, facilitating early detection and minimally invasive monitoring through liquid biopsies. These allow evaluation of the patient at multiple time points to assess treatment response, detect recurrence, resistance, and minimal residual disease, enabling timely interventions. Circulating tumor DNA (ctDNA), shed into circulation by cancer cells, represents a key component of liquid biopsies. The standard of care in oncology has been genomic profiling of tumor tissue biopsies, which can be challenging due to cost, invasiveness, and patient risk. Liquid biopsies, based on a blood draw, mitigate these disadvantages. However, the clinical utility of liquid biopsies must be established for their full integration into clinical practice [17].

6. Pathology Analysis Techniques

Several techniques are implemented in pathology analysis. Starting with histopathology, slide preparation includes fixation, processing, embedding, sectioning, and staining with hematoxylin and eosin. Large biopsy specimens may require sampling, and pathology report elements encompass tumor description, background tissue, adjunct testing, diagnosis, and staging; a critical feature checklist exists for each tumor type. The next technique is immunohistochemistry. Applications range from confirming diagnosis through cell differentiation or presence of microorganisms to predicting prognosis or treatment response. Immunofluorescence and immunogold are alternative immunohistochemical methods; immunocytochemistry uses a similar approach on cytology specimens.

Molecular biology has revolutionized cancer pathology, leading to molecular pathology. Additional new techniques include whole genome sequencing, proteomics, and metabolomics. Whole genome sequencing unveils the source of the disease, proteomics reveals the state, and metabolomics shows tumor behavior. For probing specific molecular changes in tumor samples, methods like fluorescent in situ hybridization and sequencing are employed. Complementary adjunct techniques encompass digital pathology with three-dimensional scanning and automated machine-learning artificial intelligence. [18][19][20]

6.1. Histopathology

Once frequently considered an integral and convenient final form after routine histopathologic review, specimens of both tumors and interstitial diseases of the lung acquired a new dimension from the advent of molecular biology. The remarkable range of discoveries in the past 10 years have provided enhanced insights for the study and therapy of many diseases. With continuous improvement and concomitant reduction in the cost of many procedures, the range of specimens for which informative studies can be performed has increased. Accordingly, almost all tissues suitable for histology are suitable for study by molecular methods, and preparations of material now complement each other in the practice of medicine [1]. Furthermore, the emergence of enormous databases significantly influences thought concerning disease processes. At the same time, a wide range of invaluable techniques, such as polymerase chain reaction can amplify ancient DNA, assisting approaches toward not only pathology but virtually all biological questions [21].

Despite the practical limitation for pulmonary specimens, it is now well established that reliable data from molecular methods can repeat, in most respects, the information obtained by immunohistochemistry performed on routine sections. Given the prospect of further discoveries

during the next few years, an evolution in the pathologic examination of lung diseases is likely to occur. Even so, general principles for the use of molecular techniques in lung diseases are intact regardless of the use of historical materials or those recently obtained. Procedures are discussed for means by which rooms containing both equipment and all reagents can be set up for the application of basic techniques, and for procuring the required necessary equipment and reagents at a cost that is indicated. [22][23][24]

6.2. Immunohistochemistry

Immunohistochemistry (IHC) refers to procedures that use specific immune reagents, such as antibodies, to visualize modes of expression and the distributions of antigens in cells, tissues and organs. Other detection methods use antibodies coupled to imaging nuclear magnetic resonance contrast agents, such as gadolinium, enabling labelling to be detected in vivo by magnetic resonance imaging. The antigen–antibody complex that forms is visualized by covalent binding of an enzyme, such as peroxidase, to the primary or secondary antibody, and the subsequent addition of a hydrogen peroxide solution containing a colored or fluorescent product precursor. The enzyme catalyzes the conversion of the substrate into an insoluble colored product that is deposited around the antigen and, therefore, immunostained structures appear in colors distinctive from those in the rest of the section. The use of fluorescent products permits the simultaneous localization of multiple immune reagents, although it allows fewer markers per sample than that described for fluorescent in situ hybridization.

Immunohistochemical staining is commonly used to distinguish different types of cancer or to identify the origin of a metastasis. However, or indirectly demonstrated. For example, ovarian cancer frequently metastasizes to the brain, and the expression of CA125 antigen in the brain metastasis is indicative of the ovarian primary. Occasionally, the antigen identified by immunostaining may contribute to development of treatment. Immunohistochemistry is used to classify cancers based on their expression of hormone and protein receptors. Adenocarcinomas of the breast may be evaluated for their expression of estrogen and progesterone receptors by immunohistochemistry, with the presence of receptor-defined subgroups favoring treatment with hormone therapy. Likewise, all breast carcinomas are immunostained for expression of the human epidermal growth factor receptor 2 protein. Breast carcinomas showing amplification or high-level expression of this oncogene product may be treated with trastuzumab antibody. [25][26][27]

7. Integration of Molecular Biology in Pathology

Molecular biology enhances cancer pathology analyses through fundamental molecular pathology techniques and associated digital pathology advances. While biochemical, molecular, and cellular biology provide the foundations of molecular pathology.

The recent rise of molecular biology techniques bridging genetics and biochemical expression offers orthogonal and confirmatory information for histopathological findings; morphological analyses remain the gold standard. Within pathology, molecular biology subdivides into molecular pathology and modern digital pathology.

Assessments of biological specimens using molecular techniques, typically augmented with conventional morphological approaches, typify molecular pathology, whereas digital pathology denotes those applications involving whole-slide imaging or other forms of microscopy enabling the acquisition, processing, and accumulation of digital image information.

Molecular biology drives contemporary pathology not solely through the assurance of primary diagnosis but through its facilitation of the understanding of cancer by permitting the elucidation of analytic and interpretative steps that otherwise lyse the cell apart as an individual, uncorrelated series of molecular pathways. Molecular pathology emerged as a discipline allied to cancer [28]. Many of the techniques used in both molecular and computational biology concerning the relevant cellular processes are the same or similar. Molecular pathology presents a powerful support for approximating the gestalt of cancer and prompts the holistic morphologist to formulate complex

questions that constitute the analytic steps of contemporary “microscopic” examination.

7.1. Molecular Pathology

The discovery of cellular and molecular mechanisms underlying cancer, along with the development of highly sensitive techniques to study individual molecules involved in neoplastic transformation, have propelled the application of molecular biology and biotechnology in pathological investigations of oncologic conditions. The interplay between these fields can be categorized into various levels of integration, formalized as classic pathology, molecular biology pathology, molecular pathology, and surgical pathology [28].

According to, molecular pathology represents an approach characterized by surgical pathology in which enhanced morphological assessment of tumor tissue is achieved through targeted application of molecular biology techniques. This paradigm stimulates new hypotheses and enriches pathological and clinical insights into the studied disease. It constitutes a dynamic, integrative methodology that combines traditional histopathological examination with focused molecular analysis to achieve the most appropriate interpretation of a given pathological lesion. There is a consensus that the future role of molecular pathology in dedicated cancer centers involves supporting histopathological diagnoses and tissue classification, clarifying ambiguous morphological findings, and providing evidence regarding tumor behavior, treatment response, and patient prognosis.

Molecular pathology can also serve as a substitute for time-consuming conventional laboratory tests previously performed in surgical pathology, as embodied in many biotechnological advancements used to examine neoplastic diseases. It encompasses emerging digital pathology techniques facilitating high-resolution digitization of pathology slides and enabling remote analysis and interpretation through digital platforms. The availability of a growing repertoire of commercial immunohistochemistry and in situ hybridization biomolecular markers, coupled with the prominence of novel proximity ligation assays and high-sensitivity proteomics platforms, furnishes molecular pathology with a powerful arsenal for understanding tumor behavior and progression and for evaluating therapeutic efficacy and response.

7.2. Digital Pathology

Digital pathology is the science of performing traditional pathological assessment in a digital environment. The digitization of whole slide images facilitates advances in computational pathology and artificial intelligence, transforming qualitative assessments into quantitative ones. This transition is comparable to the shift seen in genomics due to technological innovations. Digital pathology offers significant benefits for organization, analysis, sharing, teaching, telepathology, and reproducible diagnoses [29]. Despite regulatory challenges in the United States, adoption has progressed in Canada and Europe.

8. Case Studies in Cancer Pathology

Cancer pathology significantly benefits from molecular biology and biotechnology applications. Breast cancer exemplifies histopathological approaches to receptor status determination, employing immunohistochemistry and fluorescent in situ hybridization to identify estrogen receptor, progesterone receptor, and HER2 status, which are crucial for tailoring targeted therapies [2]. Lung cancer utilizes multiplex polymerase chain reaction assays on specimens obtained through bronchoscopy, fine-needle aspiration, and pleural fluid analysis, facilitating comprehensive molecular profiling to guide treatment decisions, particularly for non-small cell lung carcinoma. Colorectal cancer workflow integrates genomic and proteomic analyses to stratify patients by recurrence risk and eligibility for adjuvant chemotherapy; immunohistochemistry serves to assess mutational status, informing targeted therapeutic strategies. These cases provide insights into the profound impact of molecular biology and biotechnology in current cancer pathology practice, illustrating pathways to optimize patient management [1].

8.1. Breast Cancer

Breast cancer is the second most common cancer and the leading cause of cancer-related death among women worldwide [30]. Early detection remains a significant challenge, despite numerous studies and advancements. Techniques developed in recent years to address early detection often exhibit limitations when used in isolation. A deep understanding of the tumor's molecular heterogeneity is crucial for effective treatment planning, as different subtypes display varied prognoses and responses to therapy. For example, HER2+ breast cancer responds favorably to combined chemotherapy and targeted therapies, whereas triple-negative breast cancer (TNBC) continues to pose therapeutic challenges. Molecular subtype analysis provides more precise information regarding recurrence risk and treatment responsiveness. Traditional classifications based on hormone receptor status and gene expression analyses have become more accessible; however, discrepancies often arise since gene transcription levels do not always correlate with protein expression due to multiple regulatory factors. Comprehensive insights into breast cancer biology require high-throughput genomic, metabolomic, and proteomic data integration. Several multigene assays—such as MammaPrint, Breast Cancer Index, Oncotype Dx, and others—facilitate early detection and inform treatment decisions by predicting recurrence risk, thereby potentially preventing overtreatment. Nonetheless, routine clinical adoption awaits further validation, particularly concerning their role in guiding therapy across specific breast cancer subtypes.

8.2. Lung Cancer

Lung cancer is the leading cause of cancer deaths worldwide. Diagnostic immunohistochemistry is performed routinely to assign the major tumour type, but additional determination of prognostically or therapeutically relevant molecular information requires tissue-based laboratory assays. Although multiple commercially available assays exist, the multiplexed nature of emerging molecular analytic tools points toward the evolution of centrali-sed laboratory assay platforms coupled with specialist house-wide expertise in assay linkage and quality assurance. When applied appropriately in a multidisciplinary setting, molecular pathology can provide pivotal information that complements histopathologic assessment in all reports of lung cancer; and soon after diagnosis, may be a substantial factor in directing both initial and on-going intended patient management [31].

8.3. Colorectal Cancer

Colorectal cancer (CRC) is a major health problem worldwide and one of the leading causes of cancer-related death [32]. It is the third most common cancer in men and the second most common in women, and localised colonic lesions contribute a significant cancer burden. Approximately 2 million people develop CRC, and about 600,000 die from it each year [33]. The risk of CRC increases with age, with about 90% of cases occurring in people over 50 years. The prognosis depends on the disease stage at diagnosis, with five-year survival rates ranging from close to 100% for non-invasive, early-stage tumours to only 10% and less for tumours with distant metastasis. Pathological factors to be considered in CRC include the tumour size and type (well, moderately, or poorly differentiated; anaplastic), the stages of lymph node involvement, depth of invasion, the sites of invasion and metastasis, the presence of tumour deposits, venous thrombosis, tumour budding, and aspects of the host immune response. These factors have an effect on disease progression, prognosis, treatment options, and quality of life.

9. Ethical Considerations in Cancer Research

Many epistemic and socio-political challenges arise when approving new cancer therapeutic approaches. The emergence of molecular biology technologies induces a major influx of data that can transform medical practice [2]. Consequently, for the proper use of personalized medicine, respecting patient rights and protecting an individual's privacy become critical. Before any analysis, direct consent of the patient must be given, and it is important to limit access to sensitive

information for the patient.

9.1. Patient Consent

Consent is a key principle of all research involving patients, volunteers or personal data. Prior to any joumal publication involving a case study, the consent form must be seen by a member of the Editorial Board, or by the Editor-in-Chief. If it is felt that the level of consent is not adequate then the authors should be asked to obtain additional consent from the patient(s), their next of kin, or a relevant legal authority.

9.2. Data Privacy

The digital outcome of high-throughput molecular investigations may range from affecting a direct patient intervention to being merely of academic interest or of low practical effect. These issues highlight the crucial role of pathology departments in modern healthcare systems in achieving excellence in sample management. Standardization of procedures, integration of various diagnostics with clinical data, and an optimally structured informatics platform with dedicated rules are all vital to the effective deployment of molecular pathology. Regulatory bodies have introduced specific obligations to ensure data safety and privacy, which must be tightly maintained across data storage, transmission, and management activities.

The extensive output of high-throughput molecular analyses will soon require both structured databases and public servers capable of ensuring appropriate anonymization and equitable access, as the sheer volume, format, and handling complexity of these data cannot be managed manually. Digital image, textual, and numerical reports should be organized within adequately interconnected personnel, specimen, and investigation directories that support the centralized sharing of each molecular investigation. [34][35][36]

10. Future Trends in Cancer Pathology

Emerging technologies herald a new era of digital diagnostics. Artificial intelligence (AI) applications offer unprecedented opportunities to address global healthcare challenges through improved disease diagnosis and prognosis [28]. Histopathological image analysis and whole-slide imaging represent species for AI implementation within cancer-pathology diagnostics. Paired with big data, these smart medical imaging systems promise to radically advance the healthcare sector, prompting initiatives like the UK Government’s Global AI Sector Deal and the UCL Knowledgeqhq TrANTsform [37]. Construction of cancer repositories and registries will enable unprecedented enquiry into medical data across geographic and temporal spectrums. Cancer outbreaks, exemplified by increases in oncology admissions following earthquakes, may be studied in detail for the first time, enabling more effective policy design and disease management.

Another major challenge for medical practitioners concerns the interpretation of patient symptoms and their interrelation. Molecular profiling of disease samples reveals multiple hidden conditions that might otherwise be overlooked. Integrating medical records, life-history data, current symptoms, and environmental conditions through machine learning offers potential towards alleviating this problem. Modern complexity of medical care demands systems capable of facilitating diagnostics of comorbidities. Medicines based upon multiple pharmaceutical compounds endow individual treatment with degrees of freedom required to address such needs effectively. Diagnostics are the defining boundary condition of solutions amenable to medical practitioners, whose expertise is indispensable for successful health outcomes.

Exploiting the full capacity offered by combinatorial drug systems requires diagnostics capable of real-time monitoring of demographic statistics concerning responses to pharmaceuticals. Fleet-wide implementation of robust routine-side-effect tests provides an unparalleled resource for inferring relevant measures. Alongside incorporation of genomic profiling, such systems hold promise of expert systems capable of identifying optimal paths through multidimensional dosage spaces with minimal supervision, thus radically advancing cancer treatment. Precision profiling

and tailored therapeutics represent the future of medicine, with associated diagnostics and laboratory procedures playing central roles that pharmaceutical formulations alone cannot address.

10.1. Artificial Intelligence in Diagnostics

Artificial intelligence (AI) is poised to play a key role in cancer diagnostics and support the enabling technologies of personalized medicine [1]. Currently, many cancer analyses are performed manually by clinical experts with the use of imaging platforms such as MR, CT, ultrasound, and histopathology investigations, and the photographs of these image data are used to perform diagnoses. AI-capable automated diagnosis is helpful because it improves accuracy and efficiency, reduces working hours, enables remote diagnostics, and is independent of the diagnostic skills of human experts. Hence, automated diagnosis is gradually changing the diagnostic environment.

In cancer-tissue testing, disease diagnoses and the identification of subtypes are crucial tasks in routine pathological laboratory procedures, and immunohistochemistry plays an important role in the overall examination processes. Various AI-guided computer-aided diagnosis (CAD) systems have been proposed to obtain reliable results. For example, the diagnosis of human epidermal growth factor receptor 2 (HER2) through automated immunostaining scoring gives reproducible and quantitative measures [2].

10.2. Personalized Medicine

Identifying patients for specific treatments, the central goal of personalized medicine, has profoundly transformed oncological therapy and prognosis. Pathology is pivotal to this evolution, not only shaping the selection of patients for therapies but also contributing to the development of new treatments. The widespread adoption of target-based classification alongside traditional histology-based diagnosis enables more precise tumor categorization [38].

Large-scale investments in precision oncology have driven the rapid proliferation of molecular tests, further elevating the role of pathology in their deployment. Image-based diagnosis and molecular analysis no longer operate in isolation, underpinning the proper execution of targeted therapies and immunotherapies. Pathologists' involvement in genomic medicine begins with sample management, encompassing an understanding of the molecular testing framework and associated technical procedures. Accurate molecular diagnosis depends extensively on pre-analytical steps such as sample type and size, fixation protocols, decalcification methods, and penetration rates. Morphological control after each step ensures the adequacy of tissue and tumor cell quantities before proceeding to molecular analysis. Standardized sample-processing guidelines, adequate quality assessments, and the incorporation of molecular data into diagnostic reports are essential to achieving diagnostic precision.

The development of personalized oncology models requires integration of individual genomic and transcriptomic information with clinical history, family history, comorbidities, and lifestyle factors. Chemotherapy regimens, such as those based on 5-fluorouracil, exemplify the relevance of the DYPD gene, which encodes the key enzyme for 5-fluorouracil degradation. Reduced DYPD activity can cause toxic accumulation of the drug, leading to severe side effects [39]. Pharmaceutical agents, including chemotherapeutics, induce persistent epigenetic modifications that contribute to adverse drug side effects; these effects, which show variability in patient susceptibility, must be accounted for in personalized oncology strategies. Hypermethylation events triggered by tumor therapies may silence tumor suppressor genes, necessitating ongoing surveillance of personalized cancer treatments. Moreover, key chemotherapeutic agents often exhibit higher toxicity toward healthy progenitor brain cells than toward cancerous cells, highlighting the need for treatment modalities that target malignant tissues while sparing normal ones. Side effects of chemotherapy, such as the elevated incidence of secondary cancers, further emphasize this imperative.

11. Challenges in Molecular Biology and Biotechnology

Molecular biology techniques have expanded dramatically, while biotechnology has opened unprecedented directions [2]. Technical limitations, difficulties with interpretations, and regulatory requirements constrain the field, because instruments addressing molecular-behavior problems have more demands. Although the genomic revolution is underway, sustained growth in the field continues to face challenges.

Current regulations are stringent but unabated, permitting new applications ad libitum. Active patents have expired, and renewals or writs of continuance broadened their scope. Even if substantial patent infringements arise legally, analysis of some DNA/building-blocks may not be reagent-specific. They would therefore be regarded as common stock. If a patent does not cover the fundamental elements of the inventions, it may appear less important . By contrast, the approach leading to patentable inventions reveals invisible biomolecules capable of holding secrets about molecular processes—a major innovation in molecular biology and biotechnology.

11.1. Technical Limitations

Despite immense progress, limitations of molecular biology and biotechnology threaten to inhibit the full application for analysis of cancer pathologies. Technical limitations with versatile techniques limit the resolution of biomolecular analyses, the amount of data, and the ability to screen multiple genes. While single-nucleotide resolution is achievable for some biomolecules, analysis is generally limited to a single organelle, tissue, or cell and excludes dynamic factors such as replenishment rates or movement. Current methodology for sequencing and analyzing the proteome or metabolome cannot resolve all biomolecules at once. Additionally, novel biomolecules that may still be relevant are currently excluded from most sequencing methods. Features such as the spatial distribution of molecules or their physical and chemical surroundings cannot be analyzed directly.

In biotechnology, regulation continues to limit the application of promising new technologies to patients. Costs of some technologies remain too high to implement in a clinical setting; for example, gene therapy is an expensive treatment option for a wide group of diseases.

11.2. Regulatory Hurdles

In recent years, significant strides have been made in molecular biology and biotechnology; their increasing influence on cancer research and treatment hinges on an ability to better analyze tissue pathology. For such progress to be fully realised, however, several technical and regulatory barriers must be overcome. Molecular approaches already inform targeted therapies, where requirements often call for fresh (or frozen) samples. This greatly impedes routine use; however, techniques capable of running on formalin-fixed material, frequently accessible through hospital biobanks, are therefore most likely to offer widespread pathologist and oncologist adoption [21].

The Fluorescence in-Situ Hybridisation (FISH) system constitutes a useful diagnostic addition to pathology laboratories. By detecting gene rearrangements or amplifications – such as ALK and ROS in non-small-cell lung cancers (NSCLC), chromosomal translocations in sarcomas, or amplification of neuroblastoma-related genes – it provides important prognostic and predictive indicators to support therapy choices. Selection of appropriate molecular techniques must consider institutional tumour workload, with discussions between formulation committees, oncologists, molecular biologists and staff helping to prioritise needs during national guidelines or funding requests [1].

The impact of molecular biology on histopathology extends beyond equipment-based methodology, progressively becoming an intrinsic tool in cancer investigation. Proteomics approaches similarly offer considerable (though previously “underestimated”) advantage by uniting genetic information with biological function and tumour morphology. While a portfolio of appropriate techniques exists, understanding – along with the capacity to handle large datasets –

remains limited. Nevertheless, these approaches plausibly constitute a central pillar of future pathology. The parallels between molecular biology and pathology – particularly their mutual pursuit of tools capable of tissue analysis, tumour identification and parameter measurement – attest to the value of integration. Both approaches, when combined, strive towards achievement of common objectives [40].

Illegal attempts to elude regulation, such as undertakings involving unvalidated procedures, need to be curtailed; nonetheless, molecular biology should not suffer unnecessary restriction. Continued in-vitro research remains critical, and wide-ranging diagnostic implementation should benefit those who actively pursue it. Rather than hinder research, regulatory institutions ought to be supportive of such advancements.

12. Collaboration Between Disciplines

The integration of molecular biology and biotechnology into cancer pathology is a rapidly evolving landscape that demands cross-disciplinary collaboration. Interdisciplinary research combining molecular biology, biotechnology, pathology, and other disciplines encourages the exchange of ideas and promotes innovation [37]. Communication between specialists across fields is essential for the timely translation of scientific discoveries. Simulation-based studies align molecular-biology and pathology operative schemata and illustrate the pivotal role of biotechnology for bridging the gap between them [1]. Close cooperation between academia and industry accelerates the identification of unmet clinical needs and fosters the development and validation of novel diagnostic assays and therapeutic approaches. Coordinated efforts among academic research centres, diagnostic companies, contract-research organisations, biotechs, and pharmaceutical companies underpin the advancement of pathology analysis techniques [28].

12.1. Interdisciplinary Research

Interdisciplinary research broadly encompasses teamwork, evaluation, and dissemination of knowledge across disciplinary boundaries. Such research enhances scholarship by encouraging an integrated approach to inquiry and education. Currently, urology, basic-science biomedical researchers, and other relevant professions establish interdisciplinary groups to tackle crucial medical challenges. In this configuration, molecular biology acts as a significant support tool for enhancing pathology analysis, thereby fostering deeper comprehension of the subject matter [28].

12.2. Industry Partnerships

The development and application of novel biomedical technologies require strong partnerships among academia, industry, and healthcare sectors. This collaborative framework is widely deployed in the cost-efficient development of new medicine in various national and international projects. The healthcare sector validates and analyses the effectiveness of novel technologies through clinical trials, especially for new healthcare devices and products. Some small- and medium-sized enterprises also innovate their products from their enterprise and share the innovative products with the healthcare sector through industrial cooperation. Medical and engineering sciences achieve interdisciplinary outcome through the mutual utilization of academic resources, innovative technologies, and the studying of cutting-edge systems, especially concerning analysis tools. Furthermore, academic and industrial partners share an in-depth understanding based on their strategic alliances with major healthcare entities and pharmaceutical companies, whereby they develop practical and systemic solutions associated with the diagnosis and treatment of cancer [28].

13. Funding and Support for Cancer Research

The significance of cancer research is underscored by the disease's status as the second leading cause of global mortality, accounting for approximately 9.6 million deaths in 2018 with projections indicating a doubling of annual deaths by 2030 [2]. Substantial funding and support for cancer studies are provided by governmental agencies such as the Department of Health of the

United Kingdom, the National Cancer Institute of the United States, and the Cancer Research United States. Private and non-profit organizations, including the Institute for Cancer Research and the American Cancer Society, also make considerable financial contributions. Research grants from institutions like Imperial College London and the Charité Medical University Berlin further reinforce this commitment [1]. The combined efforts of governmental bodies, private entities, and academic institutions constitute a foundational framework for the continued advancement of cancer research.

In light of ongoing developments in molecular biology and biotechnology, future cancer pathology research is poised to proceed at an accelerated pace. Such progress will increasingly enable the elucidation of cancer mechanisms at the cellular and tissue levels, as well as facilitate the precise analysis of tumour samples. Consequently, molecular biology and biotechnology will continue to play instrumental roles in the containment and treatment of cancer.

13.1. Government Grants

The advancements in molecular biology and biotechnology have significantly enhanced pathology analysis methods for cancer research and treatment. Yet, substantial funding and concerted efforts remain essential to sustain this progress. Several governments worldwide have allocated considerable grants to cancer-related research. Despite widespread dissemination of government funding information, many universities and research institutions fail to maximize the available resources, missing abundant funding opportunities due to ineffective publicity and inadequate funding allocation. Therefore, promoting awareness of available financial assistance is crucial. In legislation addressing post-doctoral employment guidance, the Korean government increased funding, enabling many investigators to secure post-doctoral positions. Similarly, private foundations and industry collaborations constitute major income sources for research entities. Consequently, cancer researchers are encouraged to actively seek both governmental and private grants. [1] [41]

13.2. Private Sector Investment

Private sector investment in cancer research and treatment is critical for the continued development of effective solutions to the challenges posed by the disease. Government funding alone cannot meet the comprehensive needs of a multifaceted problem like cancer. Private sector involvement has accelerated the commercialization of new technologies and strengthened industrial infrastructure for biomedical research. Enormous venture investments fuel small biotechnology companies programs, which create a vibrant research ecosystem that infuses academia with relevant, application-oriented goals. It is important to consider how private-sector participation can be intensified and made more effective in the area of cancer molecular biology. The biotechnology sector is under considerable stress as a result of winnowing of public markets, and its capacity to take projects from discovery through development to market is still limited [42]. Molecular diagnostics, for example, addresses some of the most fundamental health-care questions: does a patient have a disease, does a patient have a specific organism or virus that requires special treatment, does a patient have cancer? Molecular diagnostics kits are vital auxiliary means in pharmacology, toxicology, epidemiology, and screening test systems. As such, the market for molecular diagnostics persists at a stable level regardless of economic fluctuations, because they are associated with a medical trend that does not depend on individuals' economic status and income stability [43]. Molecular diagnostics represents a knowledge-driven industry that generates high added value once a technological product has been commercialized. The demand from the private sector will continue to remain central to healthy cancer research and will remain a key factor in transitioning new technologies beyond the proof-of-principle stage. [44][45]

14. Conclusion

Molecular biology and biotechnology have transformed conventional pathology analysis by

enabling refined techniques that enhance cancer research and treatment. The development of advanced methods such as genomic sequencing, proteomics, and metabolomics facilitates comprehensive molecular, cellular, and tissue-level investigations to elucidate the origins and progression of cancer. These capabilities have pivotal implications for early detection, prevention, and the development of personalized therapies. Collaborations between academic institutions and industry partners, education and training programs, and government and private funding have created a thriving research ecosystem that drives progress against malignancy.

References:

1. S. Susman, I. Berindan-Neagoe, B. Petrushev, R. Pirlog et al., "The role of the pathology department in the preanalytical phase of molecular analyses," 2018. ncbi.nlm.nih.gov
2. P. Gulati and C. Veer Singh, "The Crucial Role of Molecular Biology in Cancer Therapy: A Comprehensive Review," 2024. ncbi.nlm.nih.gov
3. M. Angel Piris, "The use of molecular profiling for diagnosis and research in non-Hodgkin's lymphoma," 2011. ncbi.nlm.nih.gov
4. A. M Varghese and M. F Berger, "Advancing clinical oncology through genome biology and technology," 2014. ncbi.nlm.nih.gov
5. L. Ermini and P. Driguez, "The Application of Long-Read Sequencing to Cancer," 2024. ncbi.nlm.nih.gov
6. A. N. Neagu, D. Whitham, L. Seymour, N. Haaker, I. Pelkey, "Proteomics-based identification of dysregulated proteins and biomarker discovery in invasive ductal carcinoma, the most common breast cancer subtype," *Proteomes*, vol. 11, no. 1, 2023. mdpi.com
7. A. N. Neagu, D. Whitham, E. Buonanno, et al., "Proteomics and its applications in breast cancer," *Journal of Cancer Research*, vol. 2021. nih.gov
8. F. Cai, Y. Gu, Y. Ling, G. Yi, S. Zang, T. Su, Y. Liu, A. Li, "Proteomics in pancreatic cancer," Biomarker, 2025. springer.com
9. F. Danzi, R. Pacchiana, A. Mafficini, M. T. Scupoli, "To metabolomics and beyond: a technological portfolio to investigate cancer metabolism," *Nature Reviews Clinical Oncology*, vol. 2023. nature.com
10. X. Ma and F. M. Fernández, "Advances in mass spectrometry imaging for spatial cancer metabolomics," Mass spectrometry reviews, 2024. nih.gov
11. D. R. Schmidt, R. Patel, D. G. Kirsch, et al., "Metabolomics in cancer research and emerging applications in clinical oncology," CA: a cancer journal for clinicians, vol. 71, no. 1, pp. 45-67, 2021. wiley.com
12. M. Wang, M. Chen, X. Wu, X. Huang et al., "CRISPR applications in cancer diagnosis and treatment," 2023. ncbi.nlm.nih.gov
13. X. Dai, P. Blancafort, P. Wang, A. Sgro et al., "Innovative Precision Gene-Editing Tools in Personalized Cancer Medicine," 2020. ncbi.nlm.nih.gov
14. F. Javier Sanchez-Rivera and T. E. Jacks, "Applications of the CRISPR–Cas9 system in cancer biology," 2018. [PDF]
15. B. Krishna Prasanth, S. Alkhowaiter, G. Sawarkar, B. Divya Dharshini et al., "Unlocking Early Cancer Detection: Exploring Biomarkers, Circulating DNA, and Innovative Technological Approaches," 2023. ncbi.nlm.nih.gov
16. I. Palacín-Aliana, N. García-Romero, A. Asensi-Puig, J. Carrión-Navarro et al., "Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR," 2021. ncbi.nlm.nih.gov

17. B. Sisson, J. Uvalic, K. Kelly, P. Selvam et al., "Technical and Regulatory Considerations for Taking Liquid Biopsy to the Clinic: Validation of the JAX PlasmaMonitor," 2019. [PDF]

18. L. Müllauer, "Molecular pathology of cancer: the past, the present, and the future," Journal of Personalized Medicine, 2021. mdpi.com

19. V. Angerilli, F. Galuppini, F. Pagni, N. Fusco, U. Malapelle, "The role of the pathologist in the next-generation era of tumor molecular characterization," Diagnostics, vol. 11, no. 1, 2021. mdpi.com

20. S. Wang, Y. Zheng, F. Yang, L. Zhu, and X. Q. Zhu, "The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives," Signal Transduction and Targeted Therapy, vol. 6, no. 1, pp. 1-12, 2021. nature.com

21. U. Hassan, "Role of Molecular Biology in Histopathology," 2018. [PDF]

22. D. Y. Mebratie and G. G. Dagnaw, "Review of immunohistochemistry techniques: Applications, current status, and future perspectives," Seminars in diagnostic pathology, 2024. [HTML]

23. P. W. Harms, T. L. Frankel, M. Moutafi, A. Rao, D. L. Rimm, "Multiplex immunohistochemistry and immunofluorescence: a practical update for pathologists," Modern Pathology, vol. 2023, Elsevier. sciencedirect.com

24. F. Dedeurwaerdere, K. B. M. Claes, J. Van Dorpe, et al., "Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer," *Scientific Reports*, vol. 11, no. 1, 2021. nature.com

25. S. S. Mohanty, C. R. Sahoo, and R. N. Padhy, "Role of hormone receptors and HER2 as prospective molecular markers for breast cancer: An update," Genes & diseases, 2022. sciencedirect.com

26. Q. Ding, L. Huo, Y. Peng, E. C. Yoon, Z. Li, "Immunohistochemical markers for distinguishing metastatic breast carcinoma from other common malignancies: update and revisit," Seminars in Diagnostic Pathology, vol. XX, no. XX, pp. XX-XX, 2022. [HTML]

27. Y. Takahashi, E. Dungubat, H. Kusano, D. Ganbat, "Application of immunohistochemistry in the pathological diagnosis of liver tumors," *International Journal of ...*, 2021. mdpi.com

28. D. A. Moore, C. A. Young, H. T. Morris, K. A. Oien et al., "Time for change: a new training programme for morpho-molecular pathologists?," 2018. [PDF]

29. S. N. Hart, "Will Digital Pathology be as Disruptive as Genomics?," 2018. ncbi.nlm.nih.gov

30. M. Zubair, S. Wang, and N. Ali, "Advanced Approaches to Breast Cancer Classification and Diagnosis," 2021. ncbi.nlm.nih.gov

31. P. Hofman, S. Berezowska, D. Kazdal, B. Mograbi et al., "Current challenges and practical aspects of molecular pathology for non-small cell lung cancers," 2023. ncbi.nlm.nih.gov

32. P. Ahluwalia, K. Ballur, T. Leeman, A. Vashisht et al., "Incorporating Novel Technologies in Precision Oncology for Colorectal Cancer: Advancing Personalized Medicine," 2024. ncbi.nlm.nih.gov

33. L. Huth, J. Jäkel, and E. Dahl, "Molecular Diagnostic Applications in Colorectal Cancer," 2014. ncbi.nlm.nih.gov

34. B. Zhang, H. Li, K. Yu, and Z. Jin, "Molecular docking-based computational platform for high-throughput virtual screening," CCF Transactions on High Performance Computing, vol. XX, no. YY, pp. ZZ-ZZ, 2022. springer.com

35. K. Chappell, B. Francou, C. Habib, T. Huby, "Galaxy is a suitable bioinformatics platform for the molecular diagnosis of human genetic disorders using high-throughput sequencing data analysis: five years of …," *Clinical*, 2022. academia.edu

36. D. Sehnal, S. Bittrich, M. Deshpande, et al., "Mol* Viewer: modern web app for 3D visualization and analysis of large biomolecular structures," *Nucleic Acids Research*, vol. 49, no. W1, pp. W31-W37, 2021. oup.com

37. V. Angerilli, F. Galuppini, F. Pagni, N. Fusco et al., "The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization," 2021. ncbi.nlm.nih.gov

38. R. Souza da Silva, R. Pinto, L. Cirnes, and F. Schmitt, "Tissue management in precision medicine: What the pathologist needs to know in the molecular era," 2022. ncbi.nlm.nih.gov

39. S. Štambuk, D. Šundov, S. Kuret, R. Beljan et al., "Future Perspectives of Personalized Oncology," 2010. [PDF]

40. P. S. Macklin, N. Pillay, J. L. Lee, H. Pitman et al., "CM-Path Molecular Diagnostics Forum—consensus statement on the development and implementation of molecular diagnostic tests in the United Kingdom," 2019. ncbi.nlm.nih.gov

41. R. P Kulkarni, "Nano-Bio-Genesis: tracing the rise of nanotechnology and nanobiotechnology as 'big science'," 2007. ncbi.nlm.nih.gov

42. J. Hwan Seo, J. Woo Lee, and D. Cho, "The market trend analysis and prospects of cancer molecular diagnostics kits," 2018. ncbi.nlm.nih.gov

43. I. Tandon, S. Sharma, T. Nakashe, A. Nandy et al., "Current Scenario of Molecular Diagnostics in Indian Healthcare Sector," 2015. [PDF]

44. R. S. Herbst, G. Blumenthal, S. N. Khleif, et al., "Optimizing public-private partnerships to support clinical cancer research," *Cancer Institute*, 2024. [HTML]

45. C. S. Pramesh, R. A. Badwe, N. Bhoo-Pathy, C. M. Booth, et al., "Priorities for cancer research in low-and middle-income countries: a global perspective," *Nature Medicine*, vol. 28, no. 1, pp. 1-3, 2022. nature.com